Adaptive Biotechnologies Corp (ADPT) Latest Filing Signal

Based on earningsVibe SuperAnalyst™ synthesis of the latest 10-K, Adaptive Biotechnologies Corp's filing signal turned positive.

Adaptive Biotechnologies Corporation is a commercial-stage company focused on immune medicine, leveraging its proprietary platform to decode the adaptive immune system for disease diagnosis and treatment. The company operates two main segments: Minimal Residual Disease (MRD) and Immune Medicine (IM). The MRD business centers on its clonoSEQ assay, the first FDA-authorized NGS test for detecting and monitoring MRD in lymphoid malignancies, with significant payor coverage and adoption in clinical trials. The IM business utilizes its capabilities to sequence, map, and characterize T-cell receptors (TCRs) and B-cell receptors (BCRs) at scale, generating data and insights for applications in cancer and autoimmune disorders, including data licensing and target discovery services. In 2025, the company reported revenue of $277.0 million, driven by growth in its MRD segment.

Revenue is primarily driven by the clonoSEQ diagnostic test for minimal residual disease (MRD) in lymphoid malignancies, offered to clinicians and biopharmaceutical partners. The Immune Medicine segment contributes revenue through immune receptor sequencing services, data licensing, and target discovery services.